A Multi-National Study In Bladder Cancer Patients to Detect Recurrences After TURB (Trans-urethral Resection of the Bladder) Earlier With the Xpert Bladder Cancer Monitor Assay (ANTICIPATE X)

Non-muscle-invasive Bladder Cancer Clinical Trial

— ANTICIPATE X  

Official title:

Evaluation of the Xpert® Bladder Cancer Monitor Assay Compared to Cystoscopy for the Follow-up of Patients With History of Low or Intermediate Risk Non-muscle-invasive Bladder Cancer (NMIBC): an Observational Prospective International Multicenter Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03664258
• Other study ID #: ANTICIPATE X
• Status: Completed
• Start date: June 6, 2018
• Est. completion date: January 31, 2022

Study information

• Verified date: August 2021
• Source: Cepheid
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Bladder cancer is the 5th most common cancer in Europe, with more than 151,000 new cases diagnosed in 2012 (4% of the total). Bladder cancer has the highest recurrence rate of any malignancy, often as high as 70% within 5 years of successful treatment. This high recurrence rate requires diligent and accurate monitoring as a means for early diagnosis and treatment. Considering the burden associated to repeated invasive cystoscopies, there is a need for robust but accurate tests for surveillance. In that prospect, urinary molecular tests have been developed although none were deemed adequate in the European clinical guidelines to replace cystoscopies. The Xpert Bladder Cancer Monitor Assay is a qualitative in vitro diagnostic test designed to monitor for the recurrence of bladder cancer in patients previously diagnosed with this cancer. The test provides a fast and accurate result, is non-invasive and easy to perform. The aim of this study is to assess the non-inferiority of the Xpert Bladder Cancer Monitor assay in detecting recurrences in comparison to cystoscopy in the follow-up of patients with low or intermediate risk non-muscle-invasive bladder cancer (NMIBC).

Description:

Patient recruitment and follow-up are closed. The study is in analysis phase.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 852
• Est. completion date: January 31, 2022
• Est. primary completion date: December 31, 2021
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patient undergoing a follow-up cystoscopy at the time of enrolment for low or intermediate risk NMIBC patients in the follow-up phase (according to the 2017 EAU guidelines),

• Patient must accept to be followed for 1 year after enrolment cystoscopy,

• Patient who can provide urine samples naturally (e.g. no catheterization),

• 18 years or older at the time of enrolment,

• Signed informed consent.

Exclusion Criteria:

• Patient with history of NMIBC stratified at the time of enrolment as high risk according to 2017 EAU Guidelines,

• Patient with history of Muscle-Invasive Bladder Cancer (MIBC),

• Patient having undergone a TURB less than 3 months before enrolment,

• Patient having received Mitomycin C (MMC) or Bacillus Calmette-Guerin (BCG) intravesical instillations less than 3 months before enrolment (a single MMC post-operative instillation is acceptable for inclusion).

Related Conditions & MeSH terms

• Non-muscle-invasive Bladder Cancer
• Urinary Bladder Neoplasms

Intervention

Diagnostic Test:
• Xpert Bladder Cancer Monitor
The Xpert Bladder Cancer Monitor Assay is a qualitative in vitro diagnostic test designed to monitor for the recurrence of bladder cancer in patients previously diagnosed with bladder cancer. It should be used in conjunction with other clinical measures to assess disease recurrence. The test provides a fast and accurate result, is non-invasive and easy to perform.The test utilizes a voided urine specimen and measures the level of five target mRNAs (ABL1, CRH, IGF2, UPK1B, ANXA10) by means of real-time, reverse transcription-polymerase chain reaction (RT-PCR).

Locations

Country	Name	City	State
Austria	University Clinic for Urology and Andrology	Salzburg
Austria	Medical University of Vienna	Vienna
Czechia	Teaching Hospital Motol	Praha
France	CHU Toulouse / Institut Universitaire du Cancer Toulouse Oncopole	Toulouse
Germany	Klinikum Braunschweig	Braunschweig
Germany	University of Regensburg	Regensburg
Italy	Humanitas University - Gradenigo Hospital of Turin	Turin
Netherlands	Academic Medical Center	Amsterdam
Spain	Fundacio Puigvert	Barcelona
Spain	Instituto Valenciano de Oncologia	Valencia
Sweden	Sahlgrenska University Hospital	Göteborg
United Kingdom	Royal Surrey County Hospital	Guildford
United Kingdom	Sunderland City Hospital	Sunderland

Sponsors (3)

Lead Sponsor	Collaborator
Cepheid	Axonal-Biostatem, Stève Consultants

Countries where clinical trial is conducted

Austria,  Czechia,  France,  Germany,  Italy,  Netherlands,  Spain,  Sweden,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The primary endpoint is the comparison of the number of recurrences detected between the standard of care (cystoscopy) and a urine biomarker assay	The primary outcome measure is the ratio of patients presenting recurrence, comparing the number of patients with positive cystoscopies over the duration of 12 months to the number of patients with positive Xpert Bladder Cancer Monitor Assay at D0 (at enrollment).	12 months from patient enrollment in the study.
Secondary	Comparison of the number of patients with negative Xpert Bladder Cancer Monitor assay results and the number of patients with negative cystoscopy results at D0 who are not presenting with recurrent bladder cancer within 12 months of enrolment cystoscopy.	The number of patients with negative Xpert Bladder Cancer Monitor assay results will be compared to the number of patients with negative cystoscopy results at D0 who are not presenting with recurrent bladder cancer within 12 months of enrolment cystoscopy. The absence of cancer is defined as absence of suggestion of cancer on cystoscopy performed over 12 months or positive cystoscopy at 12 months not confirmed by TURB.	12 months from patient enrollment in the study.
Secondary	Comparison of the number of positive and negative tests of Xpert Bladder Cancer Monitor and cystoscopy results at the time of each NMIBC follow-up assessment.	The number of positive and negative tests of Xpert Bladder Cancer Monitor will be compared to the cystoscopy results at the time of each NMIBC follow-up assessment.	At each patient follow-up up to 12 months of study.
Secondary	EuroQol Five Dimensions Questionnaire (EQ-5D-5L questionnaire) at Day 0	Measure of the quality of life of patients with the EQ-5D-5L questionnaire at Day 0 for 5 dimensions (mobility, self-care, usual activities, pain/discomfort and anxiety/depression).	At patient enrollment
Secondary	Patient numeric scale for cystoscopy discomfort	Evaluation of patient's cystoscopy discomfort with a patient numeric scale to complete by the patient after each. The patient self-rates on a 0 (no discomfort) to 10 (maximum discomfort) numeric scale.	At each patient follow-up up to 12 months of study.
Secondary	Assessment of medical care resources consumption related to bladder cancer at 1 month after each cystoscopy.	Assessment of medical care resources consumption related to bladder cancer follow-up with the use of a patient questionnaire completed 1 month after each cystoscopy: Number of general practitioner or urologist visits performed during 1 month after the cystoscopy.; Number of hospitalization/ duration of hospitalization during 1 month after the cystoscopy; Nature of additional medical examination performed during 1 month after the cystoscopy; Nature of additional treatments received during 1 month after the cystoscopy; Number of sick leave/ duration of sick leave during 1 month after the cystoscopy	1 month after each cystoscopy through study completion.
Secondary	EuroQol health visual analogue scale at Day 0.	Measure of the patient self-rated health on a vertical visual analogue scale numbered from 0 (best health) to 100 (worst health) at Day 0.	At patient enrollment.